pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,112 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints892BioPharma Dive343BioSpace307Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7598Rare Disease1873Cardiology1741Immunology1478Hematology1321Vaccines1197Pulmonology
  • Servier acquires Edgewise's muscular dystrophy assets for $1.55 billion
    Servier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics. The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's…
    Endpoints · 3mo agoDealPositive↗ source
  • Servier to acquire Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billion
    French pharma group Servier announced it will purchase Edgewise Therapeutics' muscular dystrophy business. The transaction is valued at up to $2.65 billion, comprising a $1.55 billion upfront cash…
    STAT · 3mo agoDealPositive↗ source
← prev
page 99 of 125
next →
fda recalls70
fda medwatch60
fda press38
1185
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism474
Infectious Disease444
  • AstraZeneca reports promising triplet therapy results in liver cancer subgroup
    AstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Eli Lilly gives hospitals five days to submit 340B claims data or lose discount pricing
    Eli Lilly has issued a notice to more than 1,000 hospitals that take part in the federal 340B drug discount program, requiring them to provide comprehensive claims data within five days. The compa…
    STAT · 3mo agoRegulatoryNegative↗ source
  • CEPI allocates $62 million to accelerate three Bundibugyo Ebola vaccine candidates
    CEPI announced it will provide roughly $62 million to three groups to speed the development of vaccines targeting the Bundibugyo strain of Ebola, which is currently spreading in the Democratic Repu…
    STAT · 3mo agoDealPositive↗ source
  • Priority review voucher prices have doubled over three years, likely to remain high
    Recent reporting highlights that the price of FDA priority review vouchers has roughly doubled from three years ago. The vouchers provide a shortcut that can shave about four months off the agency…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • CRISPR-based epigenetic editing shows promise in silencing hepatitis B genes
    A new CRISPR-based technique targets the epigenome to turn off genes that drive chronic hepatitis B infection, doing so without changing the underlying DNA sequence. Tune Therapeutics reported ear…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Shionogi receives FDA nod for first oral COVID-19 post-exposure prevention pill
    Shionogi announced that the U.S. Food and Drug Administration has granted approval for its oral antiviral designed to prevent COVID-19 after exposure. The product is indicated for adults and child…
    Endpoints · 3mo agoApprovalPositive↗ source
  • Medicare withholds cost data for senior GLP-1 obesity drugs as Massachusetts sues UnitedHealth
    Medicare announced that seniors can obtain Wegovy and Zepbound for $50 a month starting in July, but the agency has not disclosed how much the program will cost taxpayers. The absence of cost tran…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Agios pays $25 million for global rights to Oscotec’s SYK inhibitor cevidoplenib
    Agios Therapeutics announced it has secured an exclusive worldwide license for Oscotec’s experimental SYK inhibitor, cevidoplenib. Under the agreement, Agios will pay $25 million up front to Oscot…
    Endpoints · 3mo agoDealNeutral↗ source
  • Avenzo Therapeutics to go public via reverse merger with Rallybio after Candid partnership ends
    On June 1, 2026, Avenzo Therapeutics announced that it will become a publicly traded company through a reverse merger with Rallybio, securing a Nasdaq listing after its previous partner, Candid, en…
    Endpoints · 3mo agoDealPositive↗ source
  • Turn Therapeutics reports faster symptom relief in Phase 2 eczema trial
    Turn Therapeutics, a California biotech, disclosed interim results from its Phase 2 study of a topical treatment for atopic dermatitis. The analysis of 50 patients indicated that skin symptoms imp…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer study
    Johnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy support
    Orphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…
    BioPharma Dive · 3mo agoPositive↗ source
  • Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumble
    Oculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • ASCO meeting highlights grief alongside cancer data, honoring late oncologist Amy Lin
    At the annual American Society of Clinical Oncology meeting, scientists presented abundant new cancer data, but this year the program also gave space to the emotional side of oncology. Outgoing pr…
    STAT · 3mo agoNeutral↗ source
  • CDC prioritizes containing Ebola spread as Trump administration proposes grant overhaul
    The CDC announced that stopping the spread of Ebola remains its top priority, emphasizing containment measures as the virus continues to pose a threat. In parallel, the Trump administration releas…
    STAT · 3mo agoNeutral↗ source
  • Eli Lilly licenses Hanmi's GLP-2 asset for $75 million upfront
    Eli Lilly has signed a licensing agreement with South Korean biotech Hanmi to acquire rights to a GLP-2 drug candidate, paying an upfront cash payment of $75 million. The deal marks Lilly's entry…
    Endpoints · 3mo agoDealNeutral↗ source
  • Military medical corps faces recruitment crisis as physicians leave for higher civilian pay
    Retired rear admiral and former congressional physician Robert Krasner argues that the U.S. military’s medical workforce is in jeopardy. He says the war in Iran has highlighted a long‑standing shor…
    STAT · 3mo agoNegative↗ source
  • General Catalyst uses Summa Health as test bed for AI-driven patient support tools
    General Catalyst bought Ohio safety‑net hospital Summa Health in October and is using it to trial new health‑technology tools. Executives from the holding company, Health Assurance Transformation C…
    STAT · 3mo agoPositive↗ source
  • Trump administration issues rules for Medicaid work requirements
    The Centers for Medicare and Medicaid Services released a rule that sets out the standards states must follow to enforce new Medicaid work requirements. The rule details who qualifies for exemptio…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo Therapeutics
    RallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
    BioPharma Dive · 3mo agoDealNeutral↗ source
  • Croatian researcher’s five-decade quest to uncover BPC-157’s potential draws FDA attention
    In 1975 a second‑year medical student at the University of Zagreb heard a lecture on stress and the stomach lining. He imagined the organ produced a natural anti‑stress chemical and set out to find…
    STAT · 3mo agoNeutral↗ source
  • FDA misses self-imposed deadline on electric shock device ban, prompting disability advocates' outcry
    The Food and Drug Administration did not issue a decision by the end of May as it had set for itself on whether to prohibit electrical shock devices used on people with intellectual disabilities an…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Hospitals grapple with patient requests for unvaccinated donor blood
    Some patients are now asking hospitals to provide blood that comes only from donors who have not received any COVID-19 vaccine, creating a new set of ethical and logistical questions. The demand r…
    STAT · 3mo agoNeutral↗ source